The Latest Exploration of Cerebrovascular Diseases: From Preclinical Research to Treatment

Dear Colleagues,

The latest exploration of cerebrovascular diseases, which encompasses a range of conditions affecting blood flow to the brain and cerebral hemodynamic status, has marked significant advancements from preclinical research to clinical treatments. Preclinical studies have delved into the intricate mechanisms of these diseases, uncovering critical insights into risk factors, genetic predispositions, and molecular pathways. Breakthroughs in neuroimaging and biomarker identification have enhanced early detection and diagnosis, paving the way for more targeted interventions.

On the diagnostic and treatment front, innovative approaches are emerging. Novel, non-invasive, and quantitative imaging techniques to assess brain hemodynamics and collateral vessel status through innovative MRI methods shape our understanding and broaden the multimodal treatment options for various neurovascular diseases, including acute ischemic stroke. Cutting-edge therapies, such as neuroprotective drugs and advanced endovascular techniques, are showing promise in reducing the impact of strokes and other cerebrovascular events. Regenerative medicine, including stem cell therapy, offers hope for repairing brain damage and restoring function. Furthermore, personalized medicine is gaining traction, with treatments tailored to the individual’s genetic and clinical profile, improving outcomes and reducing adverse effects.

Integrating artificial intelligence and machine learning revolutionizes research and clinical practice, enabling more precise diagnosis, disease progression prediction, and treatment strategy optimization. This multi-faceted approach, from preclinical discoveries to personalized treatments, signifies a new era in the fight against cerebrovascular diseases, offering hope for improved patient outcomes and quality of life.

Dr. Basil Grüter
Dr. Martina Sebök
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.